Transgene presents initial Phase I data of TG6002, highlighting the potential of the intravenous administration of its oncolytic viruses

20210409 – TG6002 AACR EN

Transgene sa
400 Boulevard Gonthier d’Andernach - Parc d'Innovation - CS80166
67405 Illkirch Graffenstaden Cedex - France |
Tel. : + 33 (0) 3 88 27 91 00

 

© 2021 Transgene - All rights reserved
Terms of use - Credits